SG11201810848PA - Heterocyclic prolinamide derivatives - Google Patents
Heterocyclic prolinamide derivativesInfo
- Publication number
- SG11201810848PA SG11201810848PA SG11201810848PA SG11201810848PA SG11201810848PA SG 11201810848P A SG11201810848P A SG 11201810848PA SG 11201810848P A SG11201810848P A SG 11201810848PA SG 11201810848P A SG11201810848P A SG 11201810848PA SG 11201810848P A SG11201810848P A SG 11201810848PA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- amd
- applicant
- prevention
- vancouver
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
Abstract
WO 17 / 222915 Al (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 28 December 2017 (28.12.2017) WIP0 I PCT omit VIII Hot o Homomomim OH ois (10) International Publication Number WO 2017/222915 Al (51) International Patent Classification: CO7D 401/14 (2006.01) A61K 31/454 (2006.01) CO7D 405/14 (2006.01) A61K 31/4192 (2006.01) C07D 409/14 (2006.01) (21) International Application Number: PCT/US2017/037768 (22) International Filing Date: 15 June 2017 (15.06.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/352,963 21 June 2016 (21.06.2016) US (71) Applicant: INCEPTION 4, INC. [US/US]; 5871 Oberlin Drive, Suite 100, San Diego, CA 92121 (US). (72) Inventors: GOMEZ, Robert; 3344 Mt. Seymour Park- way, North Vancouver, BC V7H 1G3 (CA). DING, Jinyue; 17-9088 Halston Court, Burnaby, BC V3N 0A7 (CA). OBALLA, Renata, Marcella; 1973 Custer Court, Co- quitlam, BC V3J 6R2 (CA). POWELL, David, Andrew; 1781 Napier Street, Vancouver, BC V5L 2N1 (CA). EPI- FANOV, Maxim; 2460 Trutch Street, Vancouver, BC V6K 4H4 (CA). (74) Agent: MALLON, Joseph, J.; Knobbe Martens Olson & Bear LLP, 2040 Main Street, Fourteenth Floor, Irvine, CA 92614 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: — with international search report (Art. 21(3)) (54) Title: HETEROCYCLIC PROLINAMIDE DERIVATIVES (57) : This invention is directed to novel heterocyclic prolinamide derivatives of Formula (I), and pharmaceutically acceptable salts, solvates, solvates of the salt and prodrugs thereof, useful in the prevention (e.g., delaying the onset of or reducing the risk of developing) and treatment (e.g., controlling, alleviating, or slowing the progression of) of age-related macular degeneration (AMD) and related diseases of the eye. These diseases include dry-AMD, wet-AMD, geographic atrophy, diabetic retinopathy, retinopathy of prematurity, polypoidal choroidal vasculopathy, and degenera- tion of retinal or photoreceptor cells. The invention disclosed herein is further directed to methods of prevention, slowing the progress of, and treatment of dry-AMD, wet-AMD, and geographic at- rophy, diabetic retinopathy, retinopathy of prematurity, polypoidal choroidal vasculopathy, and de- generation of retinal or photoreceptor cells, comprising: administration of a therapeutically effective amount of compound of the invention. The compounds of the invention are inhibitors of HTRA1. Thus, the compounds of the invention are useful in the prevention and treatment of a wide range of diseases mediated (in whole or in part) by HTRA1. The compounds of the invention are also useful for inhibiting HTRA1 protease activity in an eye or locus of an arthritis or related condition. H (I)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662352963P | 2016-06-21 | 2016-06-21 | |
PCT/US2017/037768 WO2017222915A1 (en) | 2016-06-21 | 2017-06-15 | Heterocyclic prolinamide derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201810848PA true SG11201810848PA (en) | 2019-01-30 |
Family
ID=60783554
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201810848PA SG11201810848PA (en) | 2016-06-21 | 2017-06-15 | Heterocyclic prolinamide derivatives |
Country Status (19)
Country | Link |
---|---|
US (2) | US11377439B2 (en) |
EP (2) | EP4257191A3 (en) |
JP (2) | JP7179721B2 (en) |
KR (2) | KR102595723B1 (en) |
CN (2) | CN114685453A (en) |
AU (2) | AU2017282651B2 (en) |
BR (1) | BR112018076614A2 (en) |
CA (1) | CA3025253A1 (en) |
DK (1) | DK3472149T3 (en) |
EA (1) | EA201990069A1 (en) |
FI (1) | FI3472149T3 (en) |
HU (1) | HUE064412T2 (en) |
IL (1) | IL263284B (en) |
MX (1) | MX2018016189A (en) |
PH (1) | PH12018502696A1 (en) |
PL (1) | PL3472149T3 (en) |
PT (1) | PT3472149T (en) |
SG (1) | SG11201810848PA (en) |
WO (1) | WO2017222915A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10526315B2 (en) | 2016-06-21 | 2020-01-07 | Orion Ophthalmology LLC | Carbocyclic prolinamide derivatives |
WO2017222915A1 (en) | 2016-06-21 | 2017-12-28 | Inception 4, Inc. | Heterocyclic prolinamide derivatives |
Family Cites Families (156)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0315574A3 (en) | 1987-11-05 | 1990-08-22 | Hoechst Aktiengesellschaft | Renin inhibitors |
US5023236A (en) | 1988-04-07 | 1991-06-11 | Corvas, Inc. | Factor VII/VIIA active site inhibitors |
DE3827340A1 (en) | 1988-08-12 | 1990-02-15 | Hoechst Ag | USE OF (ALPHA) -AMINOBORONIC ACID DERIVATIVES FOR THE PROPHYLAXIS AND TREATMENT OF VIRUS DISEASES |
US5225402A (en) | 1989-02-10 | 1993-07-06 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives |
IE910713A1 (en) | 1990-03-05 | 1991-09-11 | Cephalon Inc | Chymotrypsin-like proteases |
GB9017694D0 (en) | 1990-08-13 | 1990-09-26 | Sandoz Ltd | Improvements in or relating to organic chemistry |
GB9024129D0 (en) | 1990-11-06 | 1990-12-19 | Thrombosis Research Trust | Inhibitors and substrates of thrombin |
US5712267A (en) | 1991-06-04 | 1998-01-27 | Sankyo Company,. Limited | Carbapenem derivatives, their preparation and their use as antibiotics |
EP0644892A1 (en) | 1992-06-12 | 1995-03-29 | Pfizer Inc. | Inhibitors of angiotensin i chymase(s) including human heart chymase |
US5208313A (en) | 1992-07-16 | 1993-05-04 | Surface Coatings, Inc. | Waterproof breathable polyurethane membranes and porous substrates protected therewith |
IL109319A0 (en) | 1993-04-27 | 1994-07-31 | Du Pont Merck Pharma | Amidino and guanidino substituted boronic acid compounds |
US5658885A (en) | 1993-04-27 | 1997-08-19 | The Dupont Merck Pharmaceutical Company | Amidino and guanidino substituted boronic acid inhibitors of trypsin-like enzymes |
CA2159834A1 (en) | 1993-04-30 | 1994-11-10 | Daniel F. Veber | Thrombin inhibitors |
US5672582A (en) | 1993-04-30 | 1997-09-30 | Merck & Co., Inc. | Thrombin inhibitors |
ES2170104T3 (en) | 1993-10-01 | 2002-08-01 | Merrell Pharma Inc | INHIBITORS OF THE PRODUCTION OF BETA-AMILOID PROTEINS. |
IL111175A0 (en) | 1993-10-07 | 1994-12-29 | Du Pont Merck Pharma | Electrophilic peptide analogs as inhibitors of trypsin-like serine proteases and pharmaceutical compositions containing them |
IL111176A0 (en) | 1993-10-07 | 1994-12-29 | Du Pont Merck Pharma | Dipeptide boronic acid inhibitors of trypsin-like enzymes and pharmaceutical compositions containing them |
GB9401483D0 (en) | 1994-01-26 | 1994-03-23 | Sandoz Ltd | Organic compounds |
US6083903A (en) | 1994-10-28 | 2000-07-04 | Leukosite, Inc. | Boronic ester and acid compounds, synthesis and uses |
AU3935895A (en) | 1994-11-24 | 1996-06-17 | Takeda Chemical Industries Ltd. | Alpha-ketoamide derivatives as cathepsin l inhibitor |
US5919765A (en) | 1995-06-07 | 1999-07-06 | Cor Therapeutics, Inc. | Inhibitors of factor XA |
TW523513B (en) | 1996-03-01 | 2003-03-11 | Akzo Nobel Nv | Serine protease inhibitors |
TW442452B (en) | 1996-03-01 | 2001-06-23 | Akzo Nobel Nv | Serine protease inhibitors having an alkynylamino side chain |
BR9712544B1 (en) | 1996-10-18 | 2013-10-22 | SERINE PROTEASE INHIBITORS, PHARMACEUTICAL COMPOSITION UNDERSTANDING THE SAME AND ITS USES | |
GB9623908D0 (en) | 1996-11-18 | 1997-01-08 | Hoffmann La Roche | Amino acid derivatives |
EP1012180B1 (en) | 1997-08-11 | 2004-12-01 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis c inhibitor peptide analogues |
DE19746468A1 (en) | 1997-10-21 | 1999-04-22 | Henkel Kgaa | Mascara for temporary coloring of human hair |
WO2000008134A2 (en) | 1998-08-03 | 2000-02-17 | Novartis Ag | HUMAN HtrA SERINE PROTEASE |
AU3704500A (en) | 1999-02-19 | 2001-01-22 | University Of Iowa Research Foundation, The | Diagnostics and therapeutics for arterial wall disruptive disorders |
CA2376965A1 (en) | 1999-07-07 | 2001-01-11 | Timothy Patrick Forsyth | Peptide boronic acid inhibitors of hepatitis c virus protease |
WO2002006280A2 (en) | 2000-07-13 | 2002-01-24 | Millennium Pharamaceuticals, Inc. | INHIBITORS OF FACTOR Xa |
RU2003105221A (en) | 2000-07-21 | 2004-09-20 | Шеринг Корпорейшн (US) | NEW PEPTIDES AS INHIBITORS OF NS3-SERIN PROTEASES OF HEPATITIS C VIRUS |
US7244721B2 (en) | 2000-07-21 | 2007-07-17 | Schering Corporation | Peptides as NS3-serine protease inhibitors of hepatitis C virus |
AR029851A1 (en) | 2000-07-21 | 2003-07-16 | Dendreon Corp | NEW PEPTIDES AS INHIBITORS OF NS3-SERINA PROTEASA DEL VIRUS DE HEPATITIS C |
AU2001276988B2 (en) * | 2000-07-21 | 2007-01-25 | Dendreon Corporation | Peptides as NS3-serine protease inhibitors of hepatitis C virus |
AU2001280187A1 (en) | 2000-08-28 | 2002-03-13 | Toray Industries, Inc. | Cyclic amine derivatives |
SV2003000617A (en) | 2000-08-31 | 2003-01-13 | Lilly Co Eli | INHIBITORS OF PROTEASA PEPTIDOMIMETICA REF. X-14912M |
US6846806B2 (en) | 2000-10-23 | 2005-01-25 | Bristol-Myers Squibb Company | Peptide inhibitors of Hepatitis C virus NS3 protein |
FR2816509B1 (en) | 2000-11-15 | 2004-02-06 | Sod Conseils Rech Applic | ASSOCIATION OF CALPAIN INHIBITORS AND OXYGEN REACTIVE TRAPS |
US7172874B2 (en) | 2001-04-30 | 2007-02-06 | The Cleveland Clinic Foundation | Diagnostic methods for age related macular degeneration |
WO2002094857A1 (en) | 2001-05-23 | 2002-11-28 | The Curators Of The University Of Missouri | Inverse solid phase synthesis of peptides |
US7244815B2 (en) | 2001-05-23 | 2007-07-17 | The Curators Of The University Of Missouri | Attachment and elaboration strategies for inverse peptide synthesis |
EP1399468B1 (en) | 2001-05-30 | 2006-02-15 | Novartis AG | 2-((n-(2-amino-3-(heteroaryl or aryl)propionyl)-aminoacyl)-amino)-alkylboronic acid derivatives |
WO2003087092A2 (en) | 2002-04-11 | 2003-10-23 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hepatitis c virus ns3 - ns4 protease |
ATE503764T1 (en) | 2002-05-20 | 2011-04-15 | Bristol Myers Squibb Co | HEPATITIS C VIRUS INHIBITORS |
AU2003265264A1 (en) | 2002-07-09 | 2004-01-23 | Point Therapeutics, Inc. | Methods and compositions relating to isoleucine boroproline compounds |
ATE325611T1 (en) | 2002-09-09 | 2006-06-15 | Trigen Ltd | BORIC ACID SALTS AND THEIR USE IN THE PROVISION OF MEDICATIONS FOR THROMBOSIS TREATMENT |
US20050119226A1 (en) | 2003-09-09 | 2005-06-02 | Trigen Limited | Methods for synthesizing organoboronic compounds and products thereof |
US20050176651A1 (en) | 2002-09-09 | 2005-08-11 | Trigen Limited | Peptide boronic acids useful in making salts thereof |
US20050282757A1 (en) | 2002-09-09 | 2005-12-22 | Trigen Limited | Peptide boronic acid compounds useful in anticoagulation |
CN102267924A (en) | 2003-01-08 | 2011-12-07 | 诺华疫苗和诊断公司 | Antibacterial agents |
WO2004103270A2 (en) | 2003-04-02 | 2004-12-02 | Suntory Pharmaceutical Research Laboratories Llc | Compounds and methods for treatment of thrombosis |
WO2004092161A1 (en) | 2003-04-11 | 2004-10-28 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease |
WO2004092162A1 (en) | 2003-04-11 | 2004-10-28 | Vertex Pharmaceuticals, Incorporated | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease |
WO2004113365A2 (en) | 2003-06-05 | 2004-12-29 | Enanta Pharmaceuticals, Inc. | Hepatitis c serine protease tri-peptide inhibitors |
US7273851B2 (en) | 2003-06-05 | 2007-09-25 | Enanta Pharmaceuticals, Inc. | Tri-peptide hepatitis C serine protease inhibitors |
UY28423A1 (en) | 2003-07-18 | 2005-02-28 | Vertex Pharma | INHIBITORS OF SERINE PROTEASES, IN SPECIAL PROTEASA NS3-NS4A OF HCV.- |
MY148123A (en) | 2003-09-05 | 2013-02-28 | Vertex Pharma | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease |
TW200526686A (en) | 2003-09-18 | 2005-08-16 | Vertex Pharma | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
AU2005210631A1 (en) | 2004-01-30 | 2005-08-18 | Schering Aktiengesellschaft | Silinane compounds as cysteine protease inhibitors |
AU2005212257A1 (en) | 2004-02-04 | 2005-08-25 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
BRPI0507972A (en) | 2004-02-23 | 2007-07-24 | Tufts College | compound, pharmaceutical composition, use of a compound, method for inhibiting the proteolytic activity of a postproline cleavage enzyme and packaged pharmaceutical composition |
GB0405267D0 (en) | 2004-03-09 | 2004-04-21 | Trigen Ltd | Compounds |
GB0405280D0 (en) | 2004-03-09 | 2004-04-21 | Trigen Ltd | Compounds |
GB0405272D0 (en) | 2004-03-09 | 2004-04-21 | Trigen Ltd | Compounds |
CA2564177A1 (en) | 2004-04-30 | 2005-11-10 | Theraptosis S.A. | Caspase-2 inhibitors and their biological applications |
CN101035802A (en) | 2004-07-02 | 2007-09-12 | 健泰科生物技术公司 | Inhibitors of IAP |
FR2873695A1 (en) | 2004-07-30 | 2006-02-03 | Palumed Sa | HYBRID MOLECULES QA OR Q IS AMINOQUINOLINE AND A IS AN ANTIBIOTIC OR A RESISTANCE INHIBITOR), THEIR SYNTHESIS AND USES THEREOF AS ANTIBACTERIAL AGENT |
AU2005276635A1 (en) | 2004-08-25 | 2006-03-02 | Santhera Pharmaceuticals (Schweiz) Ag | Alpha-keto carbonyl calpain inhibitors |
AU2005276631A1 (en) | 2004-08-25 | 2006-03-02 | Santhera Pharmaceuticals (Schweiz) Ag | Alpha-keto carbonyl calpain inhibitors |
WO2006059082A1 (en) | 2004-11-30 | 2006-06-08 | Trigen Limited | Oxidised lipids as reversal agents for boronic acid drugs |
WO2006059083A1 (en) | 2004-11-30 | 2006-06-08 | Trigen Limited | Neutralising agents for boronic acid drugs |
ZA200707420B (en) * | 2005-02-14 | 2009-04-29 | Univ Iowa Res Found | Methods and reagents for treatment and diagnosis of age-related macular degeneration |
CN103920142A (en) * | 2005-02-14 | 2014-07-16 | 爱荷华大学研究基金会 | Methods And Reagents For Treatment Of Age-related Macular Degeneration |
US20060252698A1 (en) | 2005-04-20 | 2006-11-09 | Malcolm Bruce A | Compounds for inhibiting cathepsin activity |
US20070004635A1 (en) | 2005-06-02 | 2007-01-04 | Schering Corporation | Method of treating interferon non-responders using HCV protease inhibitor |
WO2006130627A2 (en) | 2005-06-02 | 2006-12-07 | Schering Corporation | Methods for treating hepatitis c |
US20060276407A1 (en) | 2005-06-02 | 2006-12-07 | Schering Corporation | Methods of treating hepatitis C virus |
US20060275366A1 (en) | 2005-06-02 | 2006-12-07 | Schering Corporation | Controlled-release formulation |
WO2006130552A2 (en) | 2005-06-02 | 2006-12-07 | Schering Corporation | Methods of treating hepatitis c virus |
US7608592B2 (en) | 2005-06-30 | 2009-10-27 | Virobay, Inc. | HCV inhibitors |
JP2009503084A (en) | 2005-08-01 | 2009-01-29 | フェノミックス コーポレーション | Hepatitis C serine protease inhibitor and use thereof |
EP2029153A2 (en) | 2006-01-27 | 2009-03-04 | Phenomix Corporation | Hepatitis c serine protease inhibitors and uses therefor |
WO2007095250A2 (en) | 2006-02-13 | 2007-08-23 | The Cleveland Clinic Foundation | Compositions and methods for inhibiting optic nerve damage |
US20070212865A1 (en) | 2006-03-08 | 2007-09-13 | Craig Amrine | Method for planarizing vias formed in a substrate |
CN101466727B (en) | 2006-04-11 | 2012-10-17 | 诺瓦提斯公司 | Hcv/hiv inhibitor and their uses |
WO2007120595A2 (en) | 2006-04-11 | 2007-10-25 | Novartis Ag | Amines for the treatment of hcv |
AR063942A1 (en) | 2006-06-06 | 2009-03-04 | Enanta Pharm Inc | HEPATITIS C VIRUS PROTEASA INHIBITING OXYMYL COMPOUNDS |
US20100305136A1 (en) | 2006-06-08 | 2010-12-02 | Johnny Yasuo Nagasawa | Quinolone analogs derivatized with sulfonic acid, sulfonate or sulfonamide |
WO2008014236A1 (en) | 2006-07-24 | 2008-01-31 | Tetralogic Pharmaceuticals Corporation | Dimeric iap inhibitors |
DK2044223T3 (en) | 2006-07-26 | 2012-10-08 | Univ Yale Inc | Diagnosis and treatment of age-related macular degeneration |
US20100166743A1 (en) | 2006-10-06 | 2010-07-01 | University Of Utah Research Foundation | Method of detecting ocular diseases and pathologic conditions and treatment of same |
EP2097448A4 (en) | 2006-12-22 | 2010-07-21 | Univ Utah Res Found | Method of detecting ocular diseases and pathologic conditions and treatment of same |
WO2008086053A1 (en) | 2007-01-03 | 2008-07-17 | Virobay, Inc. | Hcv inhibitors |
WO2008089485A2 (en) | 2007-01-19 | 2008-07-24 | The Cleveland Clinic Foundation | Carboxyethylpyrrole compounds and methods of their production |
US7972787B2 (en) | 2007-02-16 | 2011-07-05 | Massachusetts Eye And Ear Infirmary | Methods for detecting age-related macular degeneration |
EP2495249A1 (en) | 2007-02-26 | 2012-09-05 | Achillion Pharmaceuticals, Inc. | Tertiary amine substituted peptides useful as inhibitors of HCV replication |
WO2008112798A1 (en) | 2007-03-12 | 2008-09-18 | Mayo Foundation For Medical Education And Research | Treating pre-eclempsia and cardiovascular diseases |
US20100105629A1 (en) | 2007-03-23 | 2010-04-29 | Bachovchin William W | N-Substituted Peptidomimetic Inhibitors of Dipeptidylpeptidase IV |
CA2681624A1 (en) | 2007-03-23 | 2009-01-15 | Schering Corporation | P1-nonepimerizable ketoamide inhibitors of hcv ns3 protease |
EP2185524A1 (en) | 2007-05-10 | 2010-05-19 | Intermune, Inc. | Novel peptide inhibitors of hepatitis c virus replication |
TW200911290A (en) | 2007-07-02 | 2009-03-16 | Alcon Res Ltd | RNAI-mediated inhibition of HTRA1 for treatment of macular degeneration |
WO2009006473A2 (en) | 2007-07-05 | 2009-01-08 | Trustees Of Tufts College | Pro-soft polypeptide proteasome inhibitors, and methods of use thereof |
GEP20125599B (en) | 2007-08-06 | 2012-08-10 | Millennium Pharm Inc | Proteasome inhibitors |
WO2009046405A2 (en) | 2007-10-05 | 2009-04-09 | University Of Utah Research Foundation | Antibodies to htra1 and methods of using the same |
US7683636B2 (en) | 2007-10-26 | 2010-03-23 | Honeywell International Inc. | Structure for capacitive balancing of integrated relative humidity sensor |
EP2851432B1 (en) | 2007-11-01 | 2019-01-09 | University of Iowa Research Foundation | RCA locus analysis to assess susceptibility to AMD |
PL2225261T3 (en) | 2007-12-03 | 2016-09-30 | Boropeptide inhibitors of enteropeptidase and their uses in treatment of obesity, overweight and/or diseases associated with an abnormal fat metabolism | |
US8193346B2 (en) | 2007-12-06 | 2012-06-05 | Enanta Pharmaceuticals, Inc. | Process for making macrocyclic oximyl hepatitis C protease inhibitors |
WO2009100225A1 (en) | 2008-02-07 | 2009-08-13 | Virobay, Inc. | Inhibitors of cathepsin b |
US20110110857A1 (en) | 2008-03-06 | 2011-05-12 | Roberto Petracca | Mutant forms of chlamydia htra |
CN101638414B (en) | 2008-07-30 | 2014-01-08 | 江苏先声药物研究有限公司 | Peptidyl boronic acid, ester compound thereof, preparation method of peptidyl boronic acid and ester compound thereof, and use of peptidyl boronic acid and ester compound thereof |
WO2010019210A2 (en) | 2008-08-11 | 2010-02-18 | President And Fellows Of Harvard College | Halofuginone analogs for inhibition of trna synthetases and uses thereof |
AR075090A1 (en) | 2008-09-29 | 2011-03-09 | Millennium Pharm Inc | ACID DERIVATIVES 1-AMINO-2-CYCLLOBUTILETILBORONICO PROTEOSOMA INHIBITORS, USEFUL AS ANTI-BANKER AGENTS, AND PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND THEM. |
CN102203296B (en) | 2008-11-05 | 2014-12-03 | 健泰科生物技术公司 | Genetic polymorphisms in age-related macular degeneration |
WO2010132459A2 (en) | 2009-05-11 | 2010-11-18 | Cleveland Clinic Foundation | Biomarkers for assessment of age-related macular degeneration |
CN101928329B (en) | 2009-06-19 | 2013-07-17 | 北京大学 | Tripeptide boric acid (ester) compound and preparation method and application thereof |
US20110104154A1 (en) | 2009-10-30 | 2011-05-05 | Alcon Research, Ltd. | Single nucleotide polymorphisms and genes associated with age-related macular degeneration |
WO2011075607A1 (en) * | 2009-12-18 | 2011-06-23 | Intermune, Inc. | Novel inhibitors of hepatitis c virus replication |
WO2011094426A1 (en) | 2010-01-29 | 2011-08-04 | The United State Of America, As Represented By The Secretary, Department Of Health & Human Services | Caspase inhibitors |
MA34133B1 (en) | 2010-03-01 | 2013-04-03 | Onyx Therapeutics Inc | COMPOUNDS FOR INHIBITORS OF IMMUNOPROTEASOME |
US20110312996A1 (en) | 2010-05-17 | 2011-12-22 | Intermune, Inc. | Novel inhibitors of hepatitis c virus replication |
WO2011156632A2 (en) | 2010-06-09 | 2011-12-15 | Georgetown University | Compositions and methods of treatment for tumors in the nervous system |
US20120095211A1 (en) | 2010-09-22 | 2012-04-19 | Intermune, Inc. | Substituted proline inhibitors of hepatitis c virus replication |
WO2012078540A1 (en) | 2010-12-08 | 2012-06-14 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Modulating immune cell activity using cytokine-induced src homology 2 and/or high temperature requirement a-1 |
TWI617559B (en) | 2010-12-22 | 2018-03-11 | 江蘇恆瑞醫藥股份有限公司 | 2-arylimidazo[1,2-b]pyridazine, 2-phenylimidazo[1,2-a]pyridine, and 2-phenylimidazo[1,2-a]pyrazine derivatives |
RU2013145890A (en) | 2011-03-15 | 2015-04-20 | Юниверсити Оф Юта Рисерч Фаундейшн | METHODS FOR DIAGNOSIS AND TREATMENT OF VASCULAR ASSOCIATED MACULOPATHY AND ITS SYMPTOMS |
CN102807607B (en) | 2011-07-22 | 2013-10-23 | 爱博新药研发(上海)有限公司 | Fused ring heterocycle compound for restraining hepatitis c virus, midbody and application of fused ring heterocycle compound |
EP2753334B1 (en) | 2011-08-30 | 2022-10-19 | Trustees Of Tufts College | Fap-activated proteasome inhibitors for treating solid tumors |
KR102102862B1 (en) | 2011-10-14 | 2020-04-22 | 제넨테크, 인크. | ANTI-HtrA1 ANTIBODIES AND METHODS OF USE |
EP2768517A4 (en) | 2011-10-17 | 2015-03-11 | Enanta Pharm Inc | Hepatitis c virus inhibitors |
US8549645B2 (en) | 2011-10-21 | 2013-10-01 | Mcafee, Inc. | System and method for detection of denial of service attacks |
EP2814807A4 (en) | 2012-02-16 | 2015-10-07 | Rqx Pharmaceuticals Inc | Linear peptide antibiotics |
WO2013149306A1 (en) | 2012-04-05 | 2013-10-10 | Prince Henry's Institute Of Medical Research | Antibodies to htra3 |
WO2014043558A1 (en) | 2012-09-14 | 2014-03-20 | University Of Utah Research Foundation | Methods of predicting the development of amd based on chromosome 1 and chromosome 10 |
TW201446791A (en) | 2013-05-01 | 2014-12-16 | Regulus Therapeutics Inc | MicroRNA compounds and methods for modulating miR-122 |
WO2015042447A1 (en) | 2013-09-20 | 2015-03-26 | Isis Pharmaceuticals, Inc. | Targeted therapeutic nucleosides and their use |
JP6564380B2 (en) | 2013-09-20 | 2019-08-21 | ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション | Compounds for treating prostate cancer |
JP6337750B2 (en) | 2013-11-22 | 2018-06-06 | 小野薬品工業株式会社 | Compound |
US9981942B2 (en) | 2013-12-20 | 2018-05-29 | Laboratorios Del Dr. Esteve S.A. | Piperidine derivatives having multimodal activity against pain |
WO2015191677A1 (en) | 2014-06-11 | 2015-12-17 | Incyte Corporation | Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors |
WO2016100555A1 (en) | 2014-12-18 | 2016-06-23 | Inception 4, Inc. | Boronic acid derivatives and uses thereof |
AR103742A1 (en) * | 2015-02-25 | 2017-05-31 | Hoffmann La Roche | DERIVATIVES OF TRIFLUOROMETILPROPANAMIDA |
FR3034709B1 (en) | 2015-04-09 | 2017-04-14 | Michelin & Cie | PNEUMATIC HAVING AN ELECTRONIC DEVICE |
EP3294718B1 (en) * | 2015-05-11 | 2020-04-29 | H. Hoffnabb-La Roche Ag | New difluoroketamide derivatives |
HUE054093T2 (en) | 2015-10-30 | 2021-08-30 | Hoffmann La Roche | Anti-htra1 antibodies and methods of use thereof |
WO2017148967A1 (en) | 2016-03-04 | 2017-09-08 | F. Hoffmann-La Roche Ag | New difluoroketamide derivatives as htra1 inhibitors |
CN108699106B (en) | 2016-03-04 | 2021-11-30 | 豪夫迈·罗氏有限公司 | Novel trifluoromethylpropionamide derivatives as HTRA1 inhibitors |
US10526315B2 (en) * | 2016-06-21 | 2020-01-07 | Orion Ophthalmology LLC | Carbocyclic prolinamide derivatives |
WO2017222915A1 (en) * | 2016-06-21 | 2017-12-28 | Inception 4, Inc. | Heterocyclic prolinamide derivatives |
MX2018016102A (en) | 2016-06-21 | 2019-08-29 | Orion Ophthalmology LLC | Aliphatic prolinamide derivatives. |
SG10202005885VA (en) | 2016-07-01 | 2020-07-29 | Hoffmann La Roche | Antisense oligonucleotides for modulating htra1 expression |
WO2018015240A1 (en) | 2016-07-18 | 2018-01-25 | F. Hoffmann-La Roche Ag | New difluoroketamide derivatives as htra1 inhibitors |
CN109563084A (en) | 2016-08-23 | 2019-04-02 | 豪夫迈·罗氏有限公司 | Novel trifluoromethyl propanamide derivative as HTRA1 inhibitor |
JP2019526563A (en) | 2016-08-23 | 2019-09-19 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Novel difluoroketamide derivatives as HTRA1 inhibitors |
EP3625243B1 (en) | 2017-05-12 | 2023-10-18 | Universität Duisburg-Essen | Tailored cyclodepsipeptides as potent non-covalent serine protease inhibitors |
-
2017
- 2017-06-15 WO PCT/US2017/037768 patent/WO2017222915A1/en unknown
- 2017-06-15 KR KR1020197001770A patent/KR102595723B1/en active IP Right Grant
- 2017-06-15 AU AU2017282651A patent/AU2017282651B2/en active Active
- 2017-06-15 PT PT178159620T patent/PT3472149T/en unknown
- 2017-06-15 SG SG11201810848PA patent/SG11201810848PA/en unknown
- 2017-06-15 FI FIEP17815962.0T patent/FI3472149T3/en active
- 2017-06-15 CN CN202210048019.8A patent/CN114685453A/en active Pending
- 2017-06-15 JP JP2019519965A patent/JP7179721B2/en active Active
- 2017-06-15 PL PL17815962.0T patent/PL3472149T3/en unknown
- 2017-06-15 US US16/312,247 patent/US11377439B2/en active Active
- 2017-06-15 HU HUE17815962A patent/HUE064412T2/en unknown
- 2017-06-15 EP EP23186166.7A patent/EP4257191A3/en active Pending
- 2017-06-15 MX MX2018016189A patent/MX2018016189A/en unknown
- 2017-06-15 CA CA3025253A patent/CA3025253A1/en active Pending
- 2017-06-15 DK DK17815962.0T patent/DK3472149T3/en active
- 2017-06-15 KR KR1020237036445A patent/KR20230153504A/en active Application Filing
- 2017-06-15 EP EP17815962.0A patent/EP3472149B1/en active Active
- 2017-06-15 BR BR112018076614-3A patent/BR112018076614A2/en unknown
- 2017-06-15 CN CN201780038043.0A patent/CN109476637B/en active Active
- 2017-06-15 EA EA201990069A patent/EA201990069A1/en unknown
-
2018
- 2018-11-26 IL IL263284A patent/IL263284B/en active IP Right Grant
- 2018-12-19 PH PH12018502696A patent/PH12018502696A1/en unknown
-
2021
- 2021-11-05 AU AU2021261935A patent/AU2021261935B2/en active Active
-
2022
- 2022-05-06 US US17/738,872 patent/US20220267306A1/en active Pending
- 2022-11-15 JP JP2022182736A patent/JP2023027074A/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201806863WA (en) | Tetracyclic pyridone compounds as antivirals | |
SG11201908598PA (en) | Compounds useful in the treatment or prevention of a prmt5-mediated disorder | |
SG11201803757UA (en) | N-[2-(1 -benzylpiperidin-4-yl)ethyl]-4-(pyrazin-2-yl)-piperazine-1 -carboxamide derivatives and related compounds as muscarinic receptor 4 (m4) antagonists for treating neurological diseases | |
SG11201900163PA (en) | Macrocycle kinase inhibitors | |
SG11201908179UA (en) | Aryl cyclopropyl-amino-isoquinolinyl amide compounds | |
SG11201408133TA (en) | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases | |
SG11201908517XA (en) | Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating ire1-related diseases and disorders | |
SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
SG11201811230RA (en) | Compositions and methods for reducing ocular neovascularization | |
SG11201408232RA (en) | 1,2,4-triazine-6-carboxamide kinase inhibitors | |
SG11201811559WA (en) | Cancer treatment combinations | |
SG11201810371XA (en) | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF | |
SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
SG11201909245PA (en) | Methods and compositions for treating aging-associated impairments using ccr3-inhibitors | |
SG11201909680UA (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds | |
SG11201811712QA (en) | 5,7-dihydro-pyrrolo-pyridine derivatives for treating neurological and neurodegenerative diseases | |
SG11201903312VA (en) | Sulfoxyalkyl organonitro and related compounds and pharmaceutical compositions for use in medicine | |
SG11201901817SA (en) | Blood-brain barrier-penetrant dopamine-b-hydroxylase inhibitors | |
SG11201407575PA (en) | 5-amino[1,4]thiazines as bace 1 inhibitors | |
SG11201408240TA (en) | Treatment of motor and movement disorder side effects associated with parkinson's disease treatments | |
SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
SG11201804885TA (en) | Monomaleimide-functionalized platinum compounds for cancer therapy | |
SG11201901249YA (en) | Aza-indazole compounds for use in tendon and/or ligament injuries | |
SG11201809537VA (en) | Urea motif containing compounds and derivatives thereof as antibacterial drugs | |
SG11201809237RA (en) | Oxaborole esters and uses thereof |